231 related articles for article (PubMed ID: 36088370)
21. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
[TBL] [Abstract][Full Text] [Related]
22. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
[TBL] [Abstract][Full Text] [Related]
24. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
25. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
26. Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex.
Hu Z; Marti J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430338
[TBL] [Abstract][Full Text] [Related]
27. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette GP; Bear AS; Carreno BM
Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
[TBL] [Abstract][Full Text] [Related]
28. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
[TBL] [Abstract][Full Text] [Related]
29. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
30. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
Tran E; Robbins PF; Lu YC; Prickett TD; Gartner JJ; Jia L; Pasetto A; Zheng Z; Ray S; Groh EM; Kriley IR; Rosenberg SA
N Engl J Med; 2016 Dec; 375(23):2255-2262. PubMed ID: 27959684
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
[TBL] [Abstract][Full Text] [Related]
32. Inhibition mechanism of MRTX1133 on KRAS
Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
[TBL] [Abstract][Full Text] [Related]
33. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
[TBL] [Abstract][Full Text] [Related]
34. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
35. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
[TBL] [Abstract][Full Text] [Related]
36. Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer.
Zhou Y; Zou Y; Yang M; Mei S; Liu X; Han H; Zhang CD; Niu MM
J Am Chem Soc; 2022 Apr; 144(16):7117-7128. PubMed ID: 35417174
[TBL] [Abstract][Full Text] [Related]
37. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
[TBL] [Abstract][Full Text] [Related]
38. Mutation-Specific and Common Phosphotyrosine Signatures of
Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
[No Abstract] [Full Text] [Related]
39. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
40. Combined Mutation of
Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]